The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation

Leukemia Research

Volumn 35, Issue 10, 2011, Pages 1279-1285

  Holroyd, Ailsa ^a   Cross, Nicholas C P ^b,c   MacDonald, Donald H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

8p11; FGFR1; JAK2; Lymphoblastic leukaemia; Tyrosine kinase

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; JANUS KINASE 1; JANUS KINASE 2; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PROTEIN TYROSINE KINASE;

B CELL LYMPHOMA; CANCER MODEL; CELL LINEAGE; CLINICAL FEATURE; CYTOGENETICS; DISEASE ACTIVITY; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENETIC VARIABILITY; HUMAN; KARYOTYPING; MALIGNANT TRANSFORMATION; MOLECULAR DIAGNOSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY ANALYSIS; SEX RATIO; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T CELL LYMPHOMA;

ANIMALS; B-LYMPHOCYTES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; LEUKEMIA, LYMPHOID; LEUKEMIA, MYELOID; MICE; MICE, TRANSGENIC; MULTIPOTENT STEM CELLS; MUTATION; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 80052102765     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.037     Document Type: Review

References (66)

1. Bain B., Gilliland D., Horny H.-P., Vardiman J. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB and FGFR1. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 68-73. IARC Press, Lyon. 4th ed. S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri, H. Stein (Eds.).
2. Bain B.J. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica 2010, 95:696-698.
3. Gotlib J., Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008, 22:1999-2010.
4. Valent P., Pathogenesis classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 2009, 23:157-165.
5. Metzgeroth G., Walz C., Score J., Siebert R., Schnittger S., Haferlach C., et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007, 21:1183-1188.
6. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
7. Metzgeroth G., Walz C., Erben P., Popp H., Schmitt-Graeff A., Haferlach C., et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol 2008, 143:707-715.
8. Jovanovic J.V., Score J., Waghorn K., Cilloni D., Gottardi E., Metzgeroth G., et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109:4635-4640.
9. Steer E.J., Cross N.C. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002, 107:113-122.
10. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
11. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
12. Macdonald D., Aguiar R.C., Mason P.J., Goldman J.M., Cross N.C. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia 1995, 9:1628-1630.
13. Macdonald D., Reiter A., Cross N.C. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002, 107:101-107.
14. Baldazzi C., Iacobucci I., Luatti S., Ottaviani E., Marzocchi G., Paolini S., et al. B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. Leuk Res 2010.
15. Chase A., Grand F.H., Cross N.C. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007, 110:3729-3734.
16. Chen J., Deangelo D.J., Kutok J.L., Williams I.R., Lee B.H., Wadleigh M., et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004, 101:14479-14484.
17. Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P. The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). haematologica 2011;96:922-26.
18. Vainchenker W., Dusa A., Constantinescu S.N. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008, 19:385-393.
19. Patnaik M.M., Knudson R.A., Gangat N., Hanson C.A., Pardanani A., Tefferi A., et al. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur J Haematol 2010, 84:518-524.
20. Tirado C.A., Chen W., Huang L.J., Laborde C., Hiemenz M.C., Valdez F., et al. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. Leuk Res 2010.
21. Lacronique V., Boureux A., Valle V.D., Poirel H., Quang C.T., Mauchauffe M., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309-1312.
22. Peeters P., Raynaud S.D., Cools J., Wlodarska I., Grosgeorge J., Philip P., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535-2540.
23. Poitras J.L., Dal Cin P., Aster J.C., Deangelo D.J., Morton C.C. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 2008, 47:884-889.
24. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008, 22:23-30.
25. Ernst T., Score J., Deininger M., Hidalgo-Curtis C., Lackie P., Ershler W., et al. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia. British Journal of Haematology 2011, 153:43-46.
26. Mustjoki S., Hernesniemi S., Rauhala A., Kahkonen M., Almqvist A., Lundan T., et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 2009, 94:1469-1471.
27. Hidalgo-Curtis C., Chase A., Drachenberg M., Roberts M.W., Finkelstein J.Z., Mould S., et al. The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes Chromosomes Cancer 2008, 47:379-385.
28. Hagemeijer A., Graux C. ABL1 rearrangements in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 2010, 49:299-308.
29. Soler G., Radford-Weiss I., Ben-Abdelali R., Mahlaoui N., Ponceau J.F., Macintyre E.A., et al. Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation. Leukemia 2008, 22:1278-1280.
30. Erben P., Gosenca D., Muller M.C., Reinhard J., Score J., Del Valle F., et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 2010, 95:738-744.
31. Cools J., Mentens N., Odero M.D., Peeters P., Wlodarska I., Delforge M., et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood 2002, 99:1776-1784.
32. Aguiar R.C., Chase A., Coulthard S., Macdonald D.H., Carapeti M., Reiter A., et al. Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood 1997, 90:3130-3135.
33. Rosati R., La Starza R., Veronese A., Aventin A., Schwienbacher C., Vallespi T., et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 2002, 99:3857-3860.
34. Yagasaki F., Jinnai I., Yoshida S., Yokoyama Y., Matsuda A., Kusumoto S., et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). Genes Chromosomes Cancer 1999, 26:192-202.
35. Kulkarni S., Heath C., Parker S., Chase A., Iqbal S., Pocock C.F., et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res 2000, 60:3592-3598.
36. Jones A.V., Cross N.C. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 2004, 61:2912-2923.
37. Score J., Walz C., Jovanovic J.V., Jones A.V., Waghorn K., Hidalgo-Curtis C., et al. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. Leukemia 2009, 23:332-339.
38. Curtis C.E., Grand F.H., Waghorn K., Sahoo T.P., George J., Cross N.C. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. Leukemia 2007, 21:1839-1841.
39. Curtis C.E., Grand F.H., Musto P., Clark A., Murphy J., Perla G., et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007, 138:77-81.
40. Walz C., Curtis C., Schnittger S., Schultheis B., Metzgeroth G., Schoch C., et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006, 45:950-956.
41. Baxter E.J., Hochhaus A., Bolufer P., Reiter A., Fernandez J.M., Senent L., et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002, 11:1391-1397.
42. Score J., Curtis C., Waghorn K., Stalder M., Jotterand M., Grand F.H., et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006, 20:827-832.
43. Pardanani A., Reeder T., Porrata L.F., Li C.Y., Tazelaar H.D., Baxter E.J., et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003, 101:3391-3397.
44. Pawson T., Kofler M. Kinome signaling through regulated protein-protein interactions in normal and cancer cells. Curr Opin Cell Biol 2009, 21:147-153.
45. Macdonald D., Cross N.C. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy. Pathobiology 2007, 74:81-88.
46. Stover E.H., Chen J., Folens C., Lee B.H., Mentens N., Marynen P., et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 2006, 103:8078-8083.
47. Inhorn R.C., Aster J.C., Roach S.A., Slapak C.A., Soiffer R., Tantravahi R., et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 1995, 85:1881-1887.
48. Vega F., Medeiros L.J., Davuluri R., Cromwell C.C., Alkan S., Abruzzo L.V. t(8;13)-positive bilineal lymphomas: report of 6 cases. Am J Surg Pathol 2008, 32:14-20.
49. Anderson M.K., Hernandez-Hoyos G., Diamond R.A., Rothenberg E.V. Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. Development 1999, 126:3131-3148.
50. Roumiantsev S., Krause D.S., Neumann C.A., Dimitri C.A., Asiedu F., Cross N.C., et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004, 5:287-298.
51. Ren M., Li X., Cowell J.K. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. Blood 2009, 114:1576-1584.
52. Fukushima K., Matsumura I., Ezoe S., Tokunaga M., Yasumi M., Satoh Y., et al. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem 2009, 284:7719-7732.
53. Ritchie K.A., Aprikyan A.A., Bowen-Pope D.F., Norby-Slycord C.J., Conyers S., Bartelmez S., et al. The Tel-PDGFRbeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice. Leukemia 1999, 13:1790-1803.
54. Tomasson M.H., Williams I.R., Hasserjian R., Udomsakdi C., McGrath S.M., Schwaller J., et al. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 1999, 93:1707-1714.
55. Lacronique V., Boureux A., Monni R., Dumon S., Mauchauffe M., Mayeux P., et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000, 95:2076-2083.
56. Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998, 17:5321-5333.
57. Carron C., Cormier F., Janin A., Lacronique V., Giovannini M., Daniel M.T., et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000, 95:3891-3899.
58. Delaval B., Letard S., Lelievre H., Chevrier V., Daviet L., Dubreuil P., et al. Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome. Cancer Res 2005, 65:7231-7240.
59. Choudhary C., Olsen J.V., Brandts C., Cox J., Reddy P.N., Bohmer F.D., et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009, 36:326-339.
60. Bercovich D., Ganmore I., Scott L.M., Wainreb G., Birger Y., Elimelech A., et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372:1484-1492.
61. Mullighan C.G., Zhang J., Harvey R.C., Collins-Underwood J.R., Schulman B.A., Phillips L.A., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009, 106:9414-9418.
62. Russell L.J., Capasso M., Vater I., Akasaka T., Bernard O.A., Calasanz M.J., et al. Deregulated expression of cytokine receptor gene CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
63. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., Loudin M.G., Liu W., Zhang J., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
64. Hertzberg L., Vendramini E., Ganmore I., Cazzaniga G., Schmitz M., Chalker J., et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 2010, 115:1006-1017.
65. Yoda A., Yoda Y., Chiaretti S., Bar-Natan M., Mani K., Rodig S.J., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2010, 107:252-257.
66. Harvey R.C., Mullighan C.G., Chen I.M., Wharton W., Mikhail F.M., Carroll A.J., et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010.